LONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows
29th Nov 2022 07:50
(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued. Read More
(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued. Read More
(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years. Read More
Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Thursday noted that its portfolio company Autolus Therapeutics PLC had widened its third quarter loss as it continued to progress its candidate pipeline. Read More
(Alliance News) - Syncona Ltd on Monday it will expand its retinal gene therapy pipeline with the acquisition of a Florida-based biotechnology company. Read More
Syncona Ltd - London-based investor in healthcare companies - Reports small quarterly net asset value rise on gain on foreign exchange. Net asset value per share at June 30 stands at 197.7 pence per share, up 1.7% from 194.4p at March 31. Read More
(Alliance News) - Syncona Ltd on Tuesday noted half-year results of its investees, Freeline Therapeutics Holdings PLC and Achilles Therapeutics PLC. Read More
(Alliance News) - Syncona Ltd on Monday said investee Freeline Therapeutics Holdings PLC has presented partial safety and efficacy data from a phase I/II dose confirmation trial for FLT180a, a gene therapy for haemophilia B. Read More
(Alliance News) - Syncona Ltd on Thursday reported a slight increase in net asset value, but a lower total return, as the value of its holdings fell due to market volatility, as the firm skipped its dividend again. Read More
Syncona Ltd - London-based investor in healthcare companies - Announces that its portfolio company, Autolus Therapeutics PLC, has published new clinical data across multiple programmes. Autolus reports "positive" early safety and efficacy data from Auto4 in patients with T cell lymphoma and "encouraging" early safety and efficacy data from Auto1/22 in paediatric acute lymphoblastic leukaemia. Read More
(Alliance News) - Syncona Ltd said on Wednesday it invested USD54 million in neurological disorder-focused gene therapy company SwanBio Therapeutics' Series B financing round. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022. Read More
Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to USD17.3 million from USD13.8 million a year ago. Research & development costs surge to USD13.0 million from USD8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to USD236.9 million from USD266.3 million as of December 31. "The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024," Achilles says. Read More
Syncona Ltd - London-based healthcare & investment company - Reports quarterly loss for its portfolio company Autolus Therapeutics PLC as research costs rise. Net loss widens to USD42.7 million from USD39.0 million a year ago. Research & development expenses rise to USD34.0 million from USD30.7 million, Syncona explains. Read More
Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total. Read More